Clinical field study

A dog study to measure NOCITA® (bupivacaine liposome injectable suspension) effectiveness was conducted in 182 client-owned dogs undergoing knee surgery. The study design was a randomized, prospective, blinded, placebo-controlled, multicenter study using 5.3 mg/kg NOCITA by infiltration injection during surgery closure. Post-operative pain assessment was evaluated at 0-24 hours, 24-48 hours and 48-72 hours.

The primary variable for effectiveness was evaluated over the first 24-hour time interval. The percent of treatment success for NOCITA was statistically significantly greater than placebo at the first 24-hour time interval (P = 0.0322). The 24-48 hour and 48-72 hour time intervals were evaluated as secondary variables and support effective use of NOCITA for up to 72 hours of analgesia. They were statistically significantly greater than placebo, with P-values of 0.0402 and 0.0432, respectively.

clinical field study chart

Clinical References

Your convenient one-stop source for viewing, downloading and sharing important information.

Learn more >

Continuing Education

Complete an educational online course designed for Veterinarians and Veterinary Technicians to stay ahead of current trends and up-to-date on cutting-edge techniques.

Begin course now >


Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Visit >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

Experience the Difference

“We began using Nocita on patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results.  The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively.  Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications.  Nocita has quickly become standard protocol for analgesia on our cruciate ligament stabilization procedures.” 

Veterinary Surgeon

Milwaukee WI

Other therapeutics from Aratana






ENTYCE (capromorelin oral solution) provides appetite stimulation.

Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE provides safe, effective appetite stimulation.










IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.



GALLIPRANT® (gapriprant tablets)
for the control of pain and inflammation associated with osteoarthritis in dogs.

GALLIPRANT is a first-in-class piprant and a non-COX-inhibiting prostaglandin receptor antagonist (PRA). It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation, and does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.1

1Kirkby Shaw K, Rausch-Derra L, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016;2(1):3-9.

In co-promotion with Elanco






IMPORTANT SAFETY INFORMATION: Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If GALLIPRANT is used long term, appropriate monitoring is recommended. Concomitant use of GALLIPRANT with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of GALLIPRANT has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see the full Prescribing Information for more detail.